Biocartis Group NV - Asset Resilience Ratio
Biocartis Group NV (BCART) has an Asset Resilience Ratio of -0.01% as of December 2016. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check BCART PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2022)
This chart shows how Biocartis Group NV's Asset Resilience Ratio has changed over time. See Biocartis Group NV balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Biocartis Group NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Biocartis Group NV.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €-11.00K | -0.01% |
| Total Liquid Assets | €-11.00K | -0.01% |
Asset Resilience Insights
- Limited Liquidity: Biocartis Group NV maintains only -0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Biocartis Group NV Industry Peers by Asset Resilience Ratio
Compare Biocartis Group NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.12% |
|
Spectral Med Inc
TO:EDT |
Diagnostics & Research | 11.67% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Biocartis Group NV (2015–2022)
The table below shows the annual Asset Resilience Ratio data for Biocartis Group NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 1.05% | €1.20 Million ≈ $1.40 Million |
€114.28 Million ≈ $133.60 Million |
+1.25pp |
| 2020-12-31 | -0.20% | €-426.00K ≈ $-498.04K |
€210.52 Million ≈ $246.12 Million |
-0.20pp |
| 2019-12-31 | 0.00% | €-13.00K ≈ $-15.20K |
€268.32 Million ≈ $313.70 Million |
+0.00pp |
| 2016-12-31 | -0.01% | €-11.00K ≈ $-12.86K |
€141.31 Million ≈ $165.20 Million |
0.00pp |
| 2015-12-31 | -0.01% | €-11.00K ≈ $-12.86K |
€148.38 Million ≈ $173.47 Million |
-- |
About Biocartis Group NV
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progres… Read more